Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.
J Am Soc Echocardiogr. 2021 Aug;34(8):831-838. doi: 10.1016/j.echo.2021.03.010. Epub 2021 Apr 1.
Patients hospitalized with coronavirus disease 2019 (COVID-19) often have abnormal findings on transthoracic echocardiography (TTE). However, although not all abnormalities on TTE result in changes in clinical management, performing TTE in recently infected patients increases disease transmission risks. It remains unknown whether common biomarker tests, such as troponin and B-type natriuretic peptide (BNP), can help distinguish in which patients with COVID-19 TTE may be safely delayed until infection risks subside.
Using electronic health records data and chart review, the authors retrospectively studied all patients hospitalized with COVID-19 in a multisite health care system from March 1, 2020, to January 15, 2021, who underwent TTE within 14 days of their first positive COVID-19 result and had BNP and troponin measured before or within 7 days of TTE. The primary outcome was the presence of one or more urgent echocardiographic findings, defined as left ventricular ejection fraction ≤ 35%, wall motion score index ≥ 1.5, moderate or greater right ventricular dysfunction, moderate or greater pericardial effusion, intracardiac thrombus, pulmonary artery systolic pressure > 50 mm Hg, or at least moderate to severe valvular disease. Stepwise logistic regression was conducted to determine biomarkers and comorbidities associated with the outcome. The performance of a rule for classifying TTE using troponin and BNP was evaluated.
Four hundred thirty-four hospitalized and 151 intensive care unit patients with COVID-19 were included. Urgent findings on TTE were present in 105 patients (24.2%). Troponin and BNP were abnormal in 311 (71.7%). Heart failure (odds ratio, 5.41; 95% CI, 2.61-11.68), troponin > 0.04 ng/mL (odds ratio, 4.40; 95% CI, 2.05-10.05), and BNP > 100 pg/mL (odds ratio, 5.85; 95% CI, 2.35-16.09) remained significant predictors of urgent findings on TTE after stepwise selection. No urgent findings on TTE were seen in 95.1% of all patients and in 91.3% of intensive care unit patients with normal troponin and BNP.
Troponin and BNP were highly associated with urgent echocardiographic findings and may be used in triaging algorithms for determining in which patients TTE can be safely delayed until after their peak infectious window has passed.
患有 2019 年冠状病毒病(COVID-19)的住院患者常在外周胸部超声心动图(TTE)检查中发现异常。然而,尽管 TTE 的所有异常结果并不都会导致临床管理发生改变,但对近期感染的患者进行 TTE 会增加疾病传播的风险。目前尚不清楚常用的生物标志物检测(如肌钙蛋白和 B 型利钠肽(BNP))是否可以帮助区分哪些 COVID-19 患者的 TTE 可以安全延迟至感染风险降低后进行。
使用电子病历数据和图表回顾,作者回顾性研究了 2020 年 3 月 1 日至 2021 年 1 月 15 日期间在多站点医疗保健系统中因 COVID-19 住院的所有患者,这些患者在首次 COVID-19 阳性结果后 14 天内进行了 TTE,并且在 TTE 前或 TTE 后 7 天内测量了 BNP 和肌钙蛋白。主要结局是存在一个或多个紧急超声心动图发现,定义为左心室射血分数≤35%,壁运动评分指数≥1.5,中度或重度右心室功能障碍,中度或重度心包积液,心内血栓形成,肺动脉收缩压>50mm Hg,或至少中度至重度瓣膜疾病。逐步逻辑回归用于确定与结局相关的生物标志物和合并症。评估了使用肌钙蛋白和 BNP 对 TTE 进行分类的规则的性能。
共纳入 434 名住院患者和 151 名 ICU 患者的 COVID-19。105 名患者(24.2%)TTE 出现紧急发现。311 名患者(71.7%)肌钙蛋白和 BNP 异常。心力衰竭(比值比,5.41;95%置信区间,2.61-11.68)、肌钙蛋白>0.04ng/ml(比值比,4.40;95%置信区间,2.05-10.05)和 BNP>100pg/ml(比值比,5.85;95%置信区间,2.35-16.09)仍然是 TTE 出现紧急发现的显著预测因子。在逐步选择后,所有患者的 95.1%和 ICU 患者的 91.3%肌钙蛋白和 BNP 正常,未见 TTE 紧急发现。
肌钙蛋白和 BNP 与紧急超声心动图发现高度相关,可用于确定 TTE 可安全延迟至其感染高峰期过后的分诊算法。